Previous 10 | Next 10 |
Invitae to Announce First Quarter 2021 Financial Results on Tuesday, May 4, 2021 PR Newswire SAN FRANCISCO , April 20, 2021 /PRNewswire/ -- Invitae Corporation (NYSE: NVTA), a leading medical genetics company, today announced that it will report its first qua...
AstraZeneca, Loxo Oncology at Lilly, and Invitae Corporation Join the Access to Comprehensive Genomic Profiling Coalition PR Newswire WASHINGTON , April 19, 2021 /PRNewswire/ -- The Access to Comprehensive Genomic Profiling Coalition (ACGP) announced today t...
Invitae (NYSE: NVTA) has become a favorite of ARK Investment Management, a famous Tesla bull in the electric vehicle manufacturer's early days. In fact, the investment firm's CEO, Cathie Wood, has called Invitae one of her most underappreciated holdings. AR...
Study finds risk-causing genetic changes in nearly 1 in 6 patients with colorectal cancer -- Cancer-linked genetic changes associated with younger age at diagnosis -- PR Newswire SAN FRANCISCO , April 15, 2021 /PRNewswire/ -- Invitae Corporation...
Invitae (NVTA) has joined eMERGE Network, a nationwide effort organized and funded by the National Human Genome Research Institute ((NHGRI)) that connects genetic data and electronic medical record ((EMR)) systems to advance the use of genetics in healthcare.As a new clinical a...
Invitae joins NIH-sponsored study aimed at improving understanding of the links between genes and cancer, heart disease and other conditions PR Newswire SAN FRANCISCO , April 8, 2021 /PRNewswire/ -- Invitae Corporation (NYSE: NVTA), a leading medical genetics...
Investing in the biotech industry can be a long road to gains given the sector’s volatility. Even with a good understanding of the system, no one can predict which biotechnology treatment, device or therapy will give the biggest return, which makes biotechnology exchange-tr...
Oppenheimer analyst Kevin DeGeeter has upgraded shares of Invitae (NVTA) from perform to outpertform following a report of a Softbank-led investment of more than $1B.His price target is $48.DeGeeter notes that Invitae is a diagnostics company with little to no COVID-19 exposure and "we expect...
Citi expects makers of healthcare equipment to recover as vaccinations drive down COVID-19 infections and procedures return. Surging Invitae after Softbank-backed investment gets another boost as Oppenheimer upgrades the stock. Equipment makers to benefit from recovery trade Citi analysts are...
Nano-X Imaging (NNOX) +68% as FDA OKs 510(k) for Single Source Nanox.ARC Digital X-Ray.Chembio Diagnostics (CEMI) +48%.NanoVibronix (NAOV) +24%.Leaf Group Ltd. (LEAF) +19% on being acquired by Graham Holdings for $8.50 per share.dMY Technology Group (DMYD) +19%.Hoth Therapeutics (HO...
News, Short Squeeze, Breakout and More Instantly...
Labcorp Announces Winning Bid for Select Assets of Invitae PR Newswire Advances Labcorp strategy to launch and scale specialty testing in areas such as oncology and rare diseases Transaction requires court approval, with confirmation expected on May 6, 2024 ...
Invitae Enters into Agreement with Labcorp for Sale of Business PR Newswire – Labcorp Selected as Winning Bidder in Court-Supervised Sale Process, Subject to Court and Regulatory Approvals – – $239 Million Cash Bid Includes Acquisition of Substantial...
Invitae Unveils New Research for Breast Cancer Patients with Variants of Uncertain Significance PR Newswire – Study findings to be presented at the 2024 American Society of Breast Surgeons Annual Meeting – SAN FRANCISCO , April 11, 2024 /PRNewsw...